US3773919A
(en)
|
1969-10-23 |
1973-11-20 |
Du Pont |
Polylactide-drug mixtures
|
US3662333A
(en)
|
1970-09-08 |
1972-05-09 |
Bendix Corp |
Hydraulic accumulator charge detector and indicating system
|
FR2413974A1
(fr)
|
1978-01-06 |
1979-08-03 |
David Bernard |
Sechoir pour feuilles imprimees par serigraphie
|
US4485045A
(en)
|
1981-07-06 |
1984-11-27 |
Research Corporation |
Synthetic phosphatidyl cholines useful in forming liposomes
|
US4816567A
(en)
|
1983-04-08 |
1989-03-28 |
Genentech, Inc. |
Recombinant immunoglobin preparations
|
US4544545A
(en)
|
1983-06-20 |
1985-10-01 |
Trustees University Of Massachusetts |
Liposomes containing modified cholesterol for organ targeting
|
US5807715A
(en)
|
1984-08-27 |
1998-09-15 |
The Board Of Trustees Of The Leland Stanford Junior University |
Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
|
US4754065A
(en)
|
1984-12-18 |
1988-06-28 |
Cetus Corporation |
Precursor to nucleic acid probe
|
US4683195A
(en)
|
1986-01-30 |
1987-07-28 |
Cetus Corporation |
Process for amplifying, detecting, and/or-cloning nucleic acid sequences
|
US4683202A
(en)
|
1985-03-28 |
1987-07-28 |
Cetus Corporation |
Process for amplifying nucleic acid sequences
|
JPS62129297A
(ja)
|
1985-08-09 |
1987-06-11 |
Toyo Jozo Co Ltd |
カルシトニン遺伝子関連ペプチド誘導体
|
US4676980A
(en)
|
1985-09-23 |
1987-06-30 |
The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Target specific cross-linked heteroantibodies
|
US4777127A
(en)
|
1985-09-30 |
1988-10-11 |
Labsystems Oy |
Human retrovirus-related products and methods of diagnosing and treating conditions associated with said retrovirus
|
GB8601597D0
(en)
|
1986-01-23 |
1986-02-26 |
Wilson R H |
Nucleotide sequences
|
US4800159A
(en)
|
1986-02-07 |
1989-01-24 |
Cetus Corporation |
Process for amplifying, detecting, and/or cloning nucleic acid sequences
|
IL85035A0
(en)
|
1987-01-08 |
1988-06-30 |
Int Genetic Eng |
Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
|
GB8702816D0
(en)
|
1987-02-07 |
1987-03-11 |
Al Sumidaie A M K |
Obtaining retrovirus-containing fraction
|
US5219740A
(en)
|
1987-02-13 |
1993-06-15 |
Fred Hutchinson Cancer Research Center |
Retroviral gene transfer into diploid fibroblasts for gene therapy
|
US5422120A
(en)
|
1988-05-30 |
1995-06-06 |
Depotech Corporation |
Heterovesicular liposomes
|
AP129A
(en)
|
1988-06-03 |
1991-04-17 |
Smithkline Biologicals S A |
Expression of retrovirus gag protein eukaryotic cells
|
GB8823869D0
(en)
|
1988-10-12 |
1988-11-16 |
Medical Res Council |
Production of antibodies
|
US5047335A
(en)
|
1988-12-21 |
1991-09-10 |
The Regents Of The University Of Calif. |
Process for controlling intracellular glycosylation of proteins
|
US5530101A
(en)
|
1988-12-28 |
1996-06-25 |
Protein Design Labs, Inc. |
Humanized immunoglobulins
|
JP2752788B2
(ja)
|
1989-01-23 |
1998-05-18 |
カイロン コーポレイション |
感染および過剰増殖障害の為の組換え療法
|
US5116964A
(en)
|
1989-02-23 |
1992-05-26 |
Genentech, Inc. |
Hybrid immunoglobulins
|
US6673776B1
(en)
|
1989-03-21 |
2004-01-06 |
Vical Incorporated |
Expression of exogenous polynucleotide sequences in a vertebrate, mammal, fish, bird or human
|
DE69034168T3
(de)
|
1989-03-21 |
2013-04-11 |
Vical, Inc. |
Expression von exogenen Polynukleotidsequenzen in Wirbeltieren
|
US5703055A
(en)
|
1989-03-21 |
1997-12-30 |
Wisconsin Alumni Research Foundation |
Generation of antibodies through lipid mediated DNA delivery
|
DE69029036T2
(de)
|
1989-06-29 |
1997-05-22 |
Medarex Inc |
Bispezifische reagenzien für die aids-therapie
|
DK0408294T3
(da)
|
1989-07-10 |
1996-01-15 |
Amylin Pharmaceuticals Inc |
Anvendelse af en amylinantagonist til fremstilling af et lægemiddel til behandling af fedme og essentiel hypertension og beslægtede lidelser
|
WO1991002805A2
(en)
|
1989-08-18 |
1991-03-07 |
Viagene, Inc. |
Recombinant retroviruses delivering vector constructs to target cells
|
US5585362A
(en)
|
1989-08-22 |
1996-12-17 |
The Regents Of The University Of Michigan |
Adenovirus vectors for gene therapy
|
US5013556A
(en)
|
1989-10-20 |
1991-05-07 |
Liposome Technology, Inc. |
Liposomes with enhanced circulation time
|
ZA911974B
(en)
|
1990-03-21 |
1994-08-22 |
Res Dev Foundation |
Heterovesicular liposomes
|
US5427908A
(en)
|
1990-05-01 |
1995-06-27 |
Affymax Technologies N.V. |
Recombinant library screening methods
|
US5625126A
(en)
|
1990-08-29 |
1997-04-29 |
Genpharm International, Inc. |
Transgenic non-human animals for producing heterologous antibodies
|
KR100272077B1
(ko)
|
1990-08-29 |
2000-11-15 |
젠팜인터내셔날,인코포레이티드 |
이종 항체를 생산할 수 있는 전이유전자를 가진 인간이외의 동물
|
US5633425A
(en)
|
1990-08-29 |
1997-05-27 |
Genpharm International, Inc. |
Transgenic non-human animals capable of producing heterologous antibodies
|
US5661016A
(en)
|
1990-08-29 |
1997-08-26 |
Genpharm International Inc. |
Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
|
US5545806A
(en)
|
1990-08-29 |
1996-08-13 |
Genpharm International, Inc. |
Ransgenic non-human animals for producing heterologous antibodies
|
ATE164395T1
(de)
|
1990-12-03 |
1998-04-15 |
Genentech Inc |
Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften
|
US5278299A
(en)
|
1991-03-18 |
1994-01-11 |
Scripps Clinic And Research Foundation |
Method and composition for synthesizing sialylated glycosyl compounds
|
DE69233482T2
(de)
|
1991-05-17 |
2006-01-12 |
Merck & Co., Inc. |
Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
|
EP0940468A1
(en)
|
1991-06-14 |
1999-09-08 |
Genentech, Inc. |
Humanized antibody variable domain
|
WO1994004679A1
(en)
|
1991-06-14 |
1994-03-03 |
Genentech, Inc. |
Method for making humanized antibodies
|
GB9115364D0
(en)
|
1991-07-16 |
1991-08-28 |
Wellcome Found |
Antibody
|
DK0648271T3
(da)
|
1991-08-20 |
2003-07-21 |
Us Gov Health & Human Serv |
Adenovirusmedieret overførsel af gener til mave-/tarmkanal
|
AU669124B2
(en)
|
1991-09-18 |
1996-05-30 |
Kyowa Hakko Kirin Co., Ltd. |
Process for producing humanized chimera antibody
|
US5565332A
(en)
|
1991-09-23 |
1996-10-15 |
Medical Research Council |
Production of chimeric antibodies - a combinatorial approach
|
DE69229477T2
(de)
|
1991-09-23 |
1999-12-09 |
Cambridge Antibody Tech |
Methoden zur Herstellung humanisierter Antikörper
|
WO1993010218A1
(en)
|
1991-11-14 |
1993-05-27 |
The United States Government As Represented By The Secretary Of The Department Of Health And Human Services |
Vectors including foreign genes and negative selective markers
|
AU3144193A
(en)
|
1991-11-21 |
1993-06-15 |
Board Of Trustees Of The Leland Stanford Junior University |
Controlling degradation of glycoprotein oligosaccharides by extracellular glycosisases
|
GB9125623D0
(en)
|
1991-12-02 |
1992-01-29 |
Dynal As |
Cell modification
|
US5714350A
(en)
|
1992-03-09 |
1998-02-03 |
Protein Design Labs, Inc. |
Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
|
FR2688514A1
(fr)
|
1992-03-16 |
1993-09-17 |
Centre Nat Rech Scient |
Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant.
|
US5733743A
(en)
|
1992-03-24 |
1998-03-31 |
Cambridge Antibody Technology Limited |
Methods for producing members of specific binding pairs
|
EP0650370A4
(en)
|
1992-06-08 |
1995-11-22 |
Univ California |
METHODS AND COMPOSITIONS TARGETED ON SPECIFIC TISSUES.
|
WO1993025698A1
(en)
|
1992-06-10 |
1993-12-23 |
The United States Government As Represented By The |
Vector particles resistant to inactivation by human serum
|
GB2269175A
(en)
|
1992-07-31 |
1994-02-02 |
Imperial College |
Retroviral vectors
|
JPH08500017A
(ja)
|
1992-08-17 |
1996-01-09 |
ジェネンテク,インコーポレイテッド |
二特異的免疫アドヘジン
|
US6210671B1
(en)
|
1992-12-01 |
2001-04-03 |
Protein Design Labs, Inc. |
Humanized antibodies reactive with L-selectin
|
CA2145641C
(en)
|
1992-12-03 |
2008-05-27 |
Richard J. Gregory |
Pseudo-adenovirus vectors
|
US5981568A
(en)
|
1993-01-28 |
1999-11-09 |
Neorx Corporation |
Therapeutic inhibitor of vascular smooth muscle cells
|
AU6524794A
(en)
|
1993-03-24 |
1994-10-11 |
Amylin Pharmaceuticals, Inc. |
Cloned receptors and methods for screening
|
ES2188612T3
(es)
|
1993-04-22 |
2003-07-01 |
Skyepharma Inc |
Liposomas multivesiculares de ciclodextrina para encapsular compuestos farmacologicos y metodos para su uso.
|
US6180377B1
(en)
|
1993-06-16 |
2001-01-30 |
Celltech Therapeutics Limited |
Humanized antibodies
|
DE69434486T2
(de)
|
1993-06-24 |
2006-07-06 |
Advec Inc. |
Adenovirus vektoren für gentherapie
|
GB9316989D0
(en)
|
1993-08-16 |
1993-09-29 |
Lynxvale Ltd |
Binding molecules
|
US6015686A
(en)
|
1993-09-15 |
2000-01-18 |
Chiron Viagene, Inc. |
Eukaryotic layered vector initiation systems
|
CA2158937C
(en)
|
1993-09-15 |
2006-01-03 |
Thomas W. Dubensky, Jr. |
Recombinant alphavirus vectors
|
ATE437232T1
(de)
|
1993-10-25 |
2009-08-15 |
Canji Inc |
Rekombinanter adenoviren-vektor und verfahren zur verwendung
|
CN1099868C
(zh)
|
1993-11-16 |
2003-01-29 |
斯卡法玛公司 |
具有控制释放活性成分作用的囊
|
JPH07196700A
(ja)
|
1994-01-06 |
1995-08-01 |
Sando Yakuhin Kk |
抗カルシトニン抗体及びその作製方法、並びに該抗体を用いたカルシトニンの測定方法
|
US6436908B1
(en)
|
1995-05-30 |
2002-08-20 |
Duke University |
Use of exogenous β-adrenergic receptor and β-adrenergic receptor kinase gene constructs to enhance myocardial function
|
CA2158977A1
(en)
|
1994-05-09 |
1995-11-10 |
James G. Respess |
Retroviral vectors having a reduced recombination rate
|
ATE265466T1
(de)
|
1994-08-16 |
2004-05-15 |
Human Genome Sciences Inc |
Calcitoninrezeptor
|
WO1996017072A2
(en)
|
1994-11-30 |
1996-06-06 |
Chiron Viagene, Inc. |
Recombinant alphavirus vectors
|
FR2732220B1
(fr)
|
1995-03-28 |
1997-04-25 |
Oreal |
Utilisation d'un antagoniste de cgrp pour traiter les lichens et les prurits et composition obtenue
|
FR2732221B1
(fr)
|
1995-03-28 |
1997-04-25 |
Oreal |
Utilisation d'un antagoniste de cgrp pour traiter les rougeurs cutanees d'origine neurogene et composition obtenue
|
FR2732222B1
(fr)
|
1995-03-28 |
1997-04-25 |
Oreal |
Utilisation d'un antagoniste de cgrp pour le traitement des prurits et des dysesthesies oculaires et palpebraux
|
FR2732598B1
(fr)
|
1995-04-10 |
1997-05-09 |
Oreal |
Utilisation de sel de metaux alcalino-terreux pour le traitement des prurits et des dysesthesies oculaires ou palpebraux
|
EP0737471A3
(fr)
|
1995-04-10 |
2000-12-06 |
L'oreal |
Utilisation d'un sel d'une métal alcalino-terreux comme inhibiteur de TNF-alpha dans une composition unique et composition obtenue
|
EP1978033A3
(en)
|
1995-04-27 |
2008-12-24 |
Amgen Fremont Inc. |
Human antibodies derived from immunized xenomice
|
US6265150B1
(en)
|
1995-06-07 |
2001-07-24 |
Becton Dickinson & Company |
Phage antibodies
|
JPH11512396A
(ja)
|
1995-09-05 |
1999-10-26 |
スミスクライン・ビーチャム・コーポレイション |
化合物および方法
|
AU2731797A
(en)
|
1996-04-15 |
1997-11-19 |
University Of Miami |
Molecular clone of cgrp receptor component protein and uses thereof
|
DE69739286D1
(de)
|
1996-05-06 |
2009-04-16 |
Oxford Biomedica Ltd |
Rekombinationsunfähige retrovirale vektoren
|
US5746694A
(en)
|
1996-05-16 |
1998-05-05 |
Wilk; Peter J. |
Endoscope biopsy channel liner and associated method
|
AU6596096A
(en)
|
1996-07-23 |
1998-02-10 |
Smithkline Beecham Corporation |
Calcitonin gene-related peptide receptor component factor (houdc44)
|
US6586458B1
(en)
|
1996-08-16 |
2003-07-01 |
Pozen Inc. |
Methods of treating headaches using 5-HT agonists in combination with long-acting NSAIDs
|
AU4261697A
(en)
|
1996-09-09 |
1998-03-26 |
Smithkline Beecham Corporation |
Compounds and methods
|
EP0927192B1
(de)
|
1996-09-10 |
2004-05-12 |
Boehringer Ingelheim Pharma GmbH & Co.KG |
Abgewandelte aminosäuren, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
|
WO1998056779A1
(en)
|
1997-06-13 |
1998-12-17 |
Smithkline Beecham Corporation |
4-sulfinyl benzamides as calcitonin gene-related peptide receptor antagonists
|
US20030069231A1
(en)
|
1999-10-12 |
2003-04-10 |
Klaus Rudolf |
Modified aminoacids, pharmaceuticals containing these compounds and method for their production
|
US6376471B1
(en)
|
1997-10-10 |
2002-04-23 |
Johns Hopkins University |
Gene delivery compositions and methods
|
SE9704770D0
(sv)
|
1997-12-19 |
1997-12-19 |
Astra Ab |
New use
|
GB9809951D0
(en)
|
1998-05-08 |
1998-07-08 |
Univ Cambridge Tech |
Binding molecules
|
GB9809839D0
(en)
|
1998-05-09 |
1998-07-08 |
Glaxo Group Ltd |
Antibody
|
WO2000018764A1
(en)
|
1998-09-30 |
2000-04-06 |
Merck Sharp & Dohme Limited |
Benzimidazolinyl piperidines as cgrp ligands
|
US6737056B1
(en)
|
1999-01-15 |
2004-05-18 |
Genentech, Inc. |
Polypeptide variants with altered effector function
|
EP1031350A1
(en)
|
1999-02-23 |
2000-08-30 |
Warner-Lambert Company |
Use of a gabapentin-analog for the manufacture of a medicament for preventing and treating visceral pain
|
US6313097B1
(en)
|
1999-03-02 |
2001-11-06 |
Boehringer Ingelheim Pharma Kg |
Antagonists of calcitonin gene-related peptide
|
EP1158997A2
(en)
|
1999-03-09 |
2001-12-05 |
University Of Southern California |
Method of promoting myocyte proliferation and myocardial tissue repair
|
US6521609B1
(en)
|
1999-08-10 |
2003-02-18 |
Boehringer Ingelheim Pharma Kg |
Use of CGRP antagonists and CGRP release inhibitors for combating menopausal hot flushes
|
US6849425B1
(en)
|
1999-10-14 |
2005-02-01 |
Ixsys, Inc. |
Methods of optimizing antibody variable region binding affinity
|
US20020162125A1
(en)
|
2001-03-06 |
2002-10-31 |
Anne-Marie Salmon |
Methods and compositions for the modulation of neurogenic inflammatory pain and physical opiate withdrawal
|
US7193070B2
(en)
|
2001-09-27 |
2007-03-20 |
Merck & Co., Inc. |
Isolated DNA molecules encoding humanized calcitonin gene-related peptide receptor, related non-human transgenic animals and assay methods
|
US6767056B2
(en)
|
2002-01-14 |
2004-07-27 |
Shin Yeh Enterprise Co., Ltd. |
Settee with a foldable tray-support unit
|
ATE435239T1
(de)
|
2002-03-29 |
2009-07-15 |
Schering Corp |
Menschliche monoklonale antikörper gegen interleukin-5 sowie diese umfassende verfahren und zusammensetzungen
|
EP1501929B1
(de)
|
2002-05-06 |
2013-03-27 |
Noxxon Pharma AG |
Cgrp bindende nukleinsäuren
|
US20040110170A1
(en)
|
2002-05-18 |
2004-06-10 |
The Regents Of The University Of California |
Cloning and characterization of calcitonin gene related peptide receptors
|
US7345065B2
(en)
|
2002-05-21 |
2008-03-18 |
Allergan, Inc. |
Methods and compositions for alleviating pain
|
US7097467B2
(en)
|
2002-06-03 |
2006-08-29 |
Wan-Tien Chen |
Dustproof plate fixture for an electrical connector
|
NZ537315A
(en)
|
2002-06-05 |
2006-04-28 |
Bristol Myers Squibb Co |
Calcitonin gene related peptide receptor antagonists
|
CN1678634A
(zh)
|
2002-06-28 |
2005-10-05 |
多曼蒂斯有限公司 |
免疫球蛋白单个变体抗原结合区及其特异性构建体
|
NZ538615A
(en)
|
2002-08-12 |
2008-03-28 |
Actavis Group Hf |
Use of CGRP antagonist compounds for treatment of psoriasis
|
DE60335957D1
(de)
*
|
2002-10-08 |
2011-03-17 |
Rinat Neuroscience Corp |
Verfahren zur behandlung von postoperativen schmerzen durch verabreichung eines antikörpers gegen nervenwachstumsfaktor und diesen enthaltende zusammensetzungen
|
ATE472556T1
(de)
|
2002-12-02 |
2010-07-15 |
Amgen Fremont Inc |
Gegen den tumor nekrose faktor gerichtete antikörper und deren verwendungen
|
PT1575517E
(pt)
|
2002-12-24 |
2012-05-28 |
Rinat Neuroscience Corp |
Anticorpos anti-ngf e métodos de utilização dos mesmos
|
US7569364B2
(en)
*
|
2002-12-24 |
2009-08-04 |
Pfizer Inc. |
Anti-NGF antibodies and methods using same
|
JP4673295B2
(ja)
|
2003-03-14 |
2011-04-20 |
メルク・シャープ・エンド・ドーム・コーポレイション |
単環式アニリドスピロヒダントインcgrp受容体拮抗物質
|
ATE535514T1
(de)
|
2003-03-14 |
2011-12-15 |
Merck Sharp & Dohme |
Carboxamid-spirohydantoin-cgrp-rezeptor- antagonisten
|
WO2004082678A1
(en)
|
2003-03-14 |
2004-09-30 |
Merck & Co. Inc. |
Aryl spirohydantoin cgrp receptor antagonists
|
AU2004222383B2
(en)
|
2003-03-14 |
2009-10-01 |
Merck Sharp & Dohme Corp. |
Bicyclic anilide spirohydantoin CGRP receptor antagonists
|
ATE509019T1
(de)
|
2003-03-14 |
2011-05-15 |
Merck Sharp & Dohme |
Benzodiazepinspirohydantoine als cgrp- rezeptorantagonisten
|
JO2355B1
(en)
|
2003-04-15 |
2006-12-12 |
ميرك شارب اند دوم كوربوريشن |
Hereditary calcitonin polypeptide receptor antagonists
|
WO2004091514A2
(en)
|
2003-04-15 |
2004-10-28 |
Merck & Co., Inc. |
Cgrp receptor antagonists
|
WO2004097421A2
(en)
|
2003-04-29 |
2004-11-11 |
Bayer Healthcare Ag |
Diagnostics and therapeutics for diseases associated with calcitonin receptor-like receptor (calcrl)
|
WO2005009962A1
(en)
|
2003-07-15 |
2005-02-03 |
Merck & Co., Inc. |
Hydroxypyridine cgrp receptor antagonists
|
US20080070239A1
(en)
|
2003-10-29 |
2008-03-20 |
University Of Rochester |
Detection of neureopeptides associated with pelvic pain disorders and uses thereof
|
DE102004015723A1
(de)
|
2004-03-29 |
2005-10-20 |
Boehringer Ingelheim Pharma |
Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
|
US7279471B2
(en)
|
2004-04-15 |
2007-10-09 |
Boehringer Ingelheim International Gmbh |
Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions
|
DE102004018794A1
(de)
|
2004-04-15 |
2005-10-27 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
|
EP1740175A1
(de)
|
2004-04-20 |
2007-01-10 |
Boehringer Ingelheim International Gmbh |
Verwendung eines cgrp-antagonisten in kombination mit einem serotonin-wiederaufnahme-hemmer zur behandlung von migräne
|
DE102004027912A1
(de)
|
2004-06-09 |
2005-12-29 |
Grünenthal GmbH |
Substituierte Cyclopenten-Verbindungen
|
US7384930B2
(en)
|
2004-11-03 |
2008-06-10 |
Bristol-Myers Squibb Company |
Constrained compounds as CGRP-receptor antagonists
|
TWI432196B
(zh)
|
2005-01-18 |
2014-04-01 |
Euro Celtique Sa |
內臟痛的治療
|
EP1770091A1
(de)
|
2005-09-29 |
2007-04-04 |
Boehringer Ingelheim Pharma GmbH & Co. KG |
CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
|
WO2007025212A2
(en)
|
2005-08-25 |
2007-03-01 |
Wex Pharmaceuticals, Inc. |
Use of sodium channel blockers for the treatment of visceral pain or pain caused by cancer treatment
|
JP5276982B2
(ja)
|
2005-08-26 |
2013-08-28 |
ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティ |
オキシトシンの投与による頭痛の処置のための方法
|
WO2007035906A2
(en)
|
2005-09-21 |
2007-03-29 |
The Regents Of The University Of California |
Systems and methods for imaging-treatment of pain
|
US8168592B2
(en)
|
2005-10-21 |
2012-05-01 |
Amgen Inc. |
CGRP peptide antagonists and conjugates
|
EA015526B1
(ru)
|
2005-11-14 |
2011-08-30 |
Ринат Ньюросайенс Корп. |
Антагонистические антитела против пептида, связанного с геном кальцитонина, и способы их применения
|
AU2006316626A1
(en)
|
2005-11-18 |
2007-05-31 |
Merck Sharp & Dohme Corp. |
Spirohydantoin aryl CGRP receptor antagonists
|
WO2007076336A1
(en)
|
2005-12-22 |
2007-07-05 |
Eli Lilly And Company |
Treatment of migraine with anti-cgrp antibodies
|
AU2007275577A1
(en)
|
2006-07-21 |
2008-01-24 |
Vertex Pharmaceuticals Incorporated |
CGRP receptor antagonists
|
US8945505B2
(en)
|
2007-02-02 |
2015-02-03 |
Panaphix, Inc. |
Use of arsenic compounds for treatment of pain and inflammation
|
MX2010004488A
(es)
|
2007-10-23 |
2010-06-17 |
Allergan Inc |
Metodos para tratar inflamacion neurogenica cronica usando toxinas clostridiales modificadas.
|
CN106110321A
(zh)
|
2008-03-04 |
2016-11-16 |
莱布瑞斯生物公司 |
治疗炎性疼痛的方法
|
KR101304150B1
(ko)
*
|
2008-03-04 |
2013-09-05 |
라브리스 바이올로직스 인코포레이티드 |
만성 통증의 치료 방법
|
CN101902988A
(zh)
|
2008-04-25 |
2010-12-01 |
耐利克斯股份有限公司 |
支架移植物的输送***
|
WO2010006168A2
(en)
|
2008-07-09 |
2010-01-14 |
University Of Rochester |
Methods of treating cancer using and agent that modulates activity of the calcitonin-gene related peptide ("cgrp") receptor
|
JO3382B1
(ar)
|
2008-12-23 |
2019-03-13 |
Amgen Inc |
أجسام مضادة ترتبط مع مستقبل cgrp بشري
|
CN107441487B
(zh)
*
|
2009-08-28 |
2021-09-14 |
泰华制药国际有限公司 |
通过施用针对降钙素基因相关肽的拮抗性抗体来治疗内脏痛的方法
|
JO3330B1
(ar)
|
2010-06-10 |
2019-03-13 |
Lilly Co Eli |
الأجسام المضادة cgrp
|
US8669368B2
(en)
|
2010-10-12 |
2014-03-11 |
Bristol-Myers Squibb Company |
Process for the preparation of cycloheptapyridine CGRP receptor antagonists
|
MX356269B
(es)
|
2011-05-20 |
2018-05-21 |
Alderbio Holdings Llc |
Uso de anticuerpos anti-cgrp y fragmentos de anticuerpo para prevenir o inhibir la fotofobia o aversion a la luz en sujetos en necesidad de los mismos, especialmente pacientes con migraña.
|
BR112013029932A2
(pt)
|
2011-05-20 |
2017-01-31 |
Alderbio Holdings Llc |
composições anti-cgrp e usos das mesmas
|
CN108359008B
(zh)
|
2011-05-20 |
2022-03-29 |
H.伦德贝克公司 |
抗cgrp或抗cgrp-r抗体或抗体片段用于治疗或预防慢性和急性形式的腹泻的用途
|
BR112013029902A2
(pt)
*
|
2011-05-20 |
2016-12-20 |
Alderbio Holdings Llc |
produção de alta pureza de proteínas de múltiplas subunidades, tal como anticorpos, em micróbios transformados, tal como pichia pastoris
|
JP6138788B2
(ja)
|
2011-08-19 |
2017-05-31 |
アルダーバイオ・ホールディングズ・エルエルシー |
形質転換した微生物、例えばピキア・パストリス中で抗体などのマルチサブユニットタンパク質を高濃度かつ高純度で生産するための多コピー法
|
CN104136612A
(zh)
|
2012-01-10 |
2014-11-05 |
诺松制药股份公司 |
特异性结合cgrp的核酸
|
US8722060B2
(en)
|
2012-05-23 |
2014-05-13 |
William J. Binder |
Method of treating vertigo
|
EP3324376A1
(en)
|
2012-10-29 |
2018-05-23 |
NetEnt Product Services Ltd. |
Architecture for multi-player, multi-game, multi- table, multi-operator & multi-jurisdiction live casino gaming
|
KR20150140679A
(ko)
|
2013-03-15 |
2015-12-16 |
앨더 바이오파마슈티컬즈, 인코포레이티드 |
항원-특이적 b 세포를 확인하고 단리시키고, 원하는 항원에 대한 항체를 생성하기 위한 프로토콜
|
EP3597664A3
(en)
|
2013-03-15 |
2020-03-11 |
Alder Biopharmaceuticals, Inc. |
Temperature shift for high yield expression of polypeptides in yeast and other transformed cells
|
CN105492026A
(zh)
|
2013-07-03 |
2016-04-13 |
奥尔德生物制药公司 |
使用抗cgrp抗体的葡萄糖代谢的调节
|
US10556945B2
(en)
|
2014-03-21 |
2020-02-11 |
Teva Pharmaceuticals International Gmbh |
Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
|
KR102274964B1
(ko)
|
2014-03-21 |
2021-07-09 |
테바 파마슈티컬스 인터내셔널 게엠베하 |
칼시토닌 유전자-관련 펩티드에 대한 길항제 항체 및 그의 사용 방법
|
AR101875A1
(es)
|
2014-09-15 |
2017-01-18 |
Amgen Inc |
Proteína de unión a antígenos, bi-específicos del receptor anti-cgrp / receptor pac1 y usos de las mismas
|
JOP20200116A1
(ar)
|
2015-04-24 |
2017-06-16 |
Amgen Inc |
طرق لعلاج أو الوقاية من الصداع النصفي
|
AR104847A1
(es)
|
2015-06-17 |
2017-08-16 |
Lilly Co Eli |
Formulación de anticuerpo anti-cgrp
|
JP2018532728A
(ja)
|
2015-09-24 |
2018-11-08 |
テバ・ファーマシューティカルズ・インターナショナル・ゲー・エム・ベー・ハー |
(持続性)外傷後頭痛の予防、治療および低減
|
SG10201913032TA
(en)
|
2016-09-23 |
2020-02-27 |
Teva Pharmaceuticals Int Gmbh |
Treating refractory migraine
|
EA201990548A1
(ru)
|
2016-09-23 |
2019-09-30 |
Тева Фармасьютикалз Интернэшнл Гмбх |
Лечение кластерной головной боли
|
EP3840836A1
(en)
|
2018-08-22 |
2021-06-30 |
Eli Lilly and Company |
Anti-cgrp antibodies for treatment-resistant patients
|